Evidence map›Paper›PMID 30538527›Full record

ReviewInternational journal of nephrology and renovascular disease2018

Antineutrophil cytoplasmic antibody-associated vasculitis, update on molecular pathogenesis, diagnosis, and treatment.

Farid Arman, Marina Barsoum, Umut Selamet, Hania Shakeri, Olivia Wassef, Mira Mikhail, Anjay Rastogi, Ramy M Hanna

Abstract readReview
In one paragraph

Review in International journal of nephrology and renovascular disease, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. [Value of anti-neutrophil cytoplasmic antibody in assessing the severity of bronchiolitis obliterans in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Farid ArmanDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.
Marina BarsoumDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.
Umut SelametDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.
Hania ShakeriDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.
Olivia WassefDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.
Mira MikhailCollege of Biological Sciences, Biola University, La Mirada, CA, USA.
Anjay RastogiDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.
Ramy M HannaDepartment of Medicine, Division of Nephrology, UCLA David Geffen School of Medicine, Los Angeles, CA, USA, rhannamd81@yahoo.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Circulating antineutrophil cytoplasmic antibodies (ANCAs) are the central pathogenic mechanism for a group of systemic and renal syndromes called the ANCA-associated vasculitis (AAV). The nomenclature has changed from eponymous labeling to granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, and microscopic polyangiitis. These syndromes predominantly affect the pulmonary and renal systems. We also review the molecular pathology behind ANCAs and associated antigens and infections. Various clinical presentations, the multiple target organs affected, and diagnostic challenges involved in identifying these diseases are discussed. Treatment updates are also provided with regard to new studies and the now standard use of anti-CD-20 monoclonal antibodies as first-line therapy in all but the most aggressive presentations of this disease. Maintenance regimens and monitoring strategies for relapse of vasculitis and associated systemic complications are discussed.

Indexed as

ANCA associated vasculitisC-ANCAglomerulonephritisP-ANCAproteinuriarituximab

Identifiers

PMID30538527
PMCPMC6255047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.